MedTrace Logo

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

NCT03336216 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2024-07-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

BIOLOGICAL

Cabiralizumab

specified dose on specified days

DRUG

Nab-paclitaxel

specified does on specified days

DRUG

Onivyde

specified dose on specified days

BIOLOGICAL

Nivolumab

specified dose on specified days

DRUG

Fluorouracil

specified dose on specified days

DRUG

Gemcitabine

specified dose on specified days

DRUG

Oxaliplatin

specified dose on specified day

DRUG

Leucovorin

Specified dose on specified days

DRUG

Irinotecan Hydrochloride

Specified dose on specified days

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2023-06-01
Completion
2023-06-01
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Denmark
  • Germany
  • Italy
  • Japan
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03336216 on ClinicalTrials.gov